Anavex Thumped On SEC Subpoena, Probe
This article was originally published in Scrip
Executive Summary
Shares of Anavex Life Sciences Corp. were smacked on Dec. 29 – tumbling as low as 21.2% in morning trading – after the company revealed it had been hit with a subpoena from the Securities and Exchange Commission (SEC) declaring it was conducting a formal investigation of the firm.